Total
0
Shares
T-I-H-I / Shutterstock.com
Market Herald logo

Subscribe

Be the first with the news that moves the market

Abundant Natural Health is developmenting a program which will focus on Australian and international distribution, brand awareness, and sales of its expanding magnesium product range.

Recently, ANH has secured two major Australian pharmacies to stock its products, with an emphasis on its magnesium-based range. ANH’s magnesium products sit on the shelves on 500 stores across Australia with the company focusing to increase this number to 5,000. 

ANH intends to invest in marketing strategies in order to increase coverage. These can include taking on brand ambassadors and optimising social media promotion. ANH attended China’s International Import Expo last November.

Representatives from Chinese distributors and Daigou groups expressed a strong interest in establishing a commercial relationship with ANH. For the remainder of 2019, ANH will rely on Daigou shoppers and the distribution in specialist pharmacies, gift shops and increased engagement with Asian social media.

In order to achieve this, a new Chinese website has been launched by the company. ANH will expand its magnesium product range and is focusing on developing magnesium lotion, bath sachets, a hand cream, and foot lotion.

This range is expected to appeal to the 175 million global sufferers of psoriasis, and 245 million sufferers of eczema/dermatitis. “By the end of the calendar year, we expect ANH will be selling six to eight natural magnesium and salt products across Australia and into China,” General Manager Shanan Birkin said.

Click here to view the full announcement

ABT by the numbers
More From The Market Herald
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) completes recruitment for Indian COVID-19 study

ResApp Health (RAP) has completed the recruitment ahead of schedule for its Indian COVID-19 clinical study.
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito

" Botanix Pharmaceuticals (ASX:BOT) progresses clinical programs

Botanix Pharmaceuticals (BOT) progressed a number of clinical programs during the September quarter.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham

" Recce Pharmaceuticals (ASX:RCE) receives ethics approval to begin R327 trial

Recce Pharmaceuticals (RCE) has received Human Research Ethics Committee (HREC) approval to begin its phase one intravenous (IV) trial of RECCE327 (R327).